logo
Share SHARE
FONT-SIZE Plus   Neg

SMMT To Report Data In Q1, PRTA Slumps, DBVT's Viaskin Value Realized

June20-062017-lt.jpg

The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of November 20, 2017.

GAINERS

1. XOMA Corp. (XOMA)

Gained 11.44% to close Monday's (Nov.20) trading at $25.52.

News: No news

Recent events:

-- On November 6, 2017, the Company reported better-than-expected third quarter 2017 financial results.
--On October 4, 2017, the Company inked license agreements with three different companies, Tizona Therapeutics, Inc., Torch Biosciences, Inc., and LakePharma, for use of XOMA's proprietary phage display libraries for antibody discovery.
--On August 25, 2017, the Company licensed the global commercial rights to Gevokizumab to Novartis. In a separate agreement, XOMA granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.

Gevokizumab is under phase II trials in acne vulgaris; acute coronary syndromes; diabetic nephropathies; giant cell arteritis; labyrinthitis; myositis; osteoarthritis; schnitzler syndrome and scleritis.

The licensing agreements eliminate almost half of XOMA's outstanding debt, more than double its cash position, and generate potential recurring revenues through royalties, according to XOMA.

2. DBV Technologies S.A. (DBVT)

Gained 10.97% to close Monday's trading at $26.00.

News: The Company has announced positive top-line safety results from its phase III trial of Viaskin Peanut for the treatment of peanut-allergic patients.

This trial, dubbed REALISE, compared the safety of treatment with Viaskin Peanut 250 µg versus placebo for six months in patients four to 11 years of age. According to the study results, Viaskin Peanut was well-tolerated with no new or unexpected adverse events.

Last month, the Company reported top-line results from a phase III trial which evaluated the safety and efficacy of Viaskin Peanut in children four to 11 years of age. In this trial, dubbed PEPITES, although the results showed a statistically significant response than placebo with a favorable tolerability profile, the primary endpoint was not met. The news sent the stock plunging 53% that day. (Oct.23, 2017).

Armed with the positive REALISE trial data, the Company intends to move ahead with its planned regulatory discussions in the United States, Europe and other countries for use of Viaskin Peanut in patients four to 11 years of age.

3. Summit Therapeutics plc (SMMT)

Gained 9.37% to close Monday's trading at $11.79.

News: The Company announced that it has completed the initial 24-weeks of dosing of Ezutromid in patients with Duchenne muscular dystrophy (DMD) in its phase II trial called PhaseOut DMD.

PhaseOut DMD is a 48-week trial that has enrolled 40 patients at sites in the UK and the U.S.

Near-term catalysts:

-- Report 24-week data from the PhaseOut DMD trial in Q1, 2018.
-- Report 48-week data from the PhaseOut DMD trial in Q3, 2018.

LOSERS

1. Prothena Corporation plc (PRTA)

Lost 14.12% to close Monday's trading at $44.60.

News: Wedbush has downgraded the stock to Neutral from Outperform, and has reduced the price target to $55 from $75.

Near-term catalysts:

-- Top-line results from a phase IIb study of NEOD001 in previously treated subjects with light chain (AL) Amyloidosis, dubbed PRONTO, are expected in the second quarter of 2018.
-- Clinical development of PRX004 for the treatment of ATTR amyloidosis is expected to begin around mid-2018.
-- A phase II study of PRX002/RG7935 for the treatment of Parkinson's disease, initiated in the second quarter of 2017, is underway.

2. Spero Therapeutics Inc. (SPRO)

Lost 12.22% to close Monday's trading at $12.72.

News: No news

Recent events:

-- The Company's stock made its debut on The Nasdaq Global Select Market on November 2, 2017, at an offering price of $14.00 per share.
-- Last month, the Company initiated a phase I safety, tolerability, and pharmacokinetics study of ORAL SPR994 in healthy subjects.

Near term catalyst:

-- If the phase I study results are positive, a pivotal phase III clinical trial of of ORAL SPR994 in patients with complicated urinary tract infections (cUTI) is planned for second half of 2018.

3. Bioverativ Inc. (BIVV)

Lost 9.53% to close Monday's trading at $50.76.

News: No news

Near-term catalysts:

-- A phase 1/2a trial of BIVV001 for hemophilia A is underway, and the first patient is expected to be dosed shortly.
-- A phase III trial of BIVV009 for Cold Agglutinin Disease is expected to begin by this year end.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT